Compare Stocks: PACB, TXG, FTRE, and ALMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$29.94 +3.5%	$30.54	$18.84 ▼ $39.61	$2.08B	N/A	420,896 shs	277,831 shs
FTRE Fortrea	$20.82 +4.0%	$20.31	$8.55 ▼ $26.16	$1.98B	1.93	1.56 million shs	560,184 shs
PACB Pacific Biosciences of California	$2.50 +6.2%	$1.85	$1.07 ▼ $3.43	$775.52M	2.19	8.21 million shs	3.73 million shs
TXG 10x Genomics	$65.84 +6.8%	$74.10	$12.80 ▼ $102.81	$8.58B	1.99	3.01 million shs	1.16 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	-5.42%	-4.77%	-15.77%	+6.75%	+2,893,999,900.00%
FTRE Fortrea	-5.97%	-15.99%	+0.10%	+11.28%	+91.40%
PACB Pacific Biosciences of California	-9.96%	+4.44%	-7.48%	+63.19%	+0.43%
TXG 10x Genomics	-12.10%	-15.53%	-34.09%	+28.77%	+351.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$29.94 +3.5%	$30.54	$18.84 ▼ $39.61	$2.08B	N/A	420,896 shs	277,831 shs
FTRE Fortrea	$20.82 +4.0%	$20.31	$8.55 ▼ $26.16	$1.98B	1.93	1.56 million shs	560,184 shs
PACB Pacific Biosciences of California	$2.50 +6.2%	$1.85	$1.07 ▼ $3.43	$775.52M	2.19	8.21 million shs	3.73 million shs
TXG 10x Genomics	$65.84 +6.8%	$74.10	$12.80 ▼ $102.81	$8.58B	1.99	3.01 million shs	1.16 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	-5.42%	-4.77%	-15.77%	+6.75%	+2,893,999,900.00%
FTRE Fortrea	-5.97%	-15.99%	+0.10%	+11.28%	+91.40%
PACB Pacific Biosciences of California	-9.96%	+4.44%	-7.48%	+63.19%	+0.43%
TXG 10x Genomics	-12.10%	-15.53%	-34.09%	+28.77%	+351.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMR Alamar Biosciences	2.43	Hold	$31.80	6.21% Upside
FTRE Fortrea	2.46	Hold	$23.95	15.08% Upside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	-31.36% Downside
TXG 10x Genomics	2.22	Hold	$68.00	3.28% Upside

Current Analyst Ratings Breakdown

Latest PACB, TXG, FTRE, and ALMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/2/2026	FTRE Fortrea	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$23.00 ➝ $26.00
10/30/2026	FTRE Fortrea	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$21.50
10/30/2026	FTRE Fortrea	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$26.00 ➝ $29.00
10/30/2026	FTRE Fortrea	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$22.00 ➝ $27.00
10/30/2026	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$23.00 ➝ $26.00
10/29/2026	FTRE Fortrea	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Strong-Buy
10/23/2026	ALMR Alamar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C-) ➝ Sell (D+)
10/23/2026	TXG 10x Genomics	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Overweight ➝ Equal Weight
10/20/2026	FTRE Fortrea	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$22.00 ➝ $24.00
10/15/2026	FTRE Fortrea	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	FTRE Fortrea	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$20.00 ➝ $25.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMR Alamar Biosciences	$100.42M	20.69	N/A	N/A	N/A	∞
FTRE Fortrea	$2.72B	0.73	$7.98 per share	2.61	$6.10 per share	3.41
PACB Pacific Biosciences of California	$159.27M	4.87	$0.69 per share	3.59	$0.02 per share	124.75
TXG 10x Genomics	$616.91M	13.91	N/A	N/A	$6.24 per share	10.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMR Alamar Biosciences	-$29.82M	-$1.96	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	-$986.20M	-$0.73	N/A	20.21	0.62	-3.18%	10.72%	2.17%	N/A
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
TXG 10x Genomics	-$43.54M	-$0.59	N/A	N/A	N/A	-12.18%	-9.33%	-7.30%	11/5/2026 (Estimated)

Latest PACB, TXG, FTRE, and ALMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	TXG 10x Genomics	-$0.2670	N/A	N/A	N/A	$147.96 million	N/A
11/3/2026	Q3 2026	PACB Pacific Biosciences of California	-$0.1260	N/A	N/A	N/A	$43.82 million	N/A
10/29/2026	Q3 2026	FTRE Fortrea	$0.2172	$0.28	+$0.0628	$0.01	$671.57 million	$691.50 million
8/11/2026	Q2 2026	ALMR Alamar Biosciences	-$0.36	-$0.22	+$0.14	-$0.22	N/A	$29.43 million
8/6/2026	Q2 2026	TXG 10x Genomics	-$0.2431	-$0.14	+$0.1031	-$0.14	$146.67 million	$151.04 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMR Alamar Biosciences	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMR Alamar Biosciences	0.03	11.85	10.23
FTRE Fortrea	1.98	0.96	0.96
PACB Pacific Biosciences of California	N/A	4.92	4.03
TXG 10x Genomics	N/A	5.69	5.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMR Alamar Biosciences	N/A
FTRE Fortrea	N/A
PACB Pacific Biosciences of California	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
ALMR Alamar Biosciences	N/A
FTRE Fortrea	0.73%
PACB Pacific Biosciences of California	3.70%
TXG 10x Genomics	8.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMR Alamar Biosciences	222	69.39 million	N/A	N/A
FTRE Fortrea	14,300	95.10 million	95.80 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable
TXG 10x Genomics	1,178	130.29 million	118.77 million	Optionable

PACB, TXG, FTRE, and ALMR Headlines

Recent News About These Companies

Torex Gold Resources (TSE:TXG) Share Price Crosses Above 200-Day Moving Average – Here’s Why

November 3 at 4:00 AM | defenseworld.netD

10x Genomics Appoints Two New Directors to Board

November 2 at 4:51 PM | tipranks.com

10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound

November 2 at 4:18 PM | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Stock Price Down 6.5% - Here's What Happened

November 2 at 1:39 PM | marketbeat.com

10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis

November 2 at 9:00 AM | prnewswire.com

10x Genomics $TXG Stock Sold by Sumitomo Mitsui Trust Group Inc.

November 2 at 7:41 AM | marketbeat.com

Will TXG Stock Ever Get Back To Its Old High?

October 30, 2026 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Shares Gap Down - Here's Why

October 30, 2026 | marketbeat.com

3 Promising Genomics Stocks to Add to Your Portfolio Now

October 30, 2026 | zacks.com

10x Genomics $TXG Stock: Simplify Asset Management Inc. Lowers Stake

October 29, 2026 | marketbeat.com

10x Genomics (TXG) Expected to Announce Earnings on Thursday

October 29, 2026 | marketbeat.com

10x Genomics: Atera Takes Off, But Valuation Flies Too High

October 28, 2026 | seekingalpha.com

10x Genomics (NASDAQ:TXG) Shares Climb 8% - Here's What Happened

October 28, 2026 | marketbeat.com

10x Genomics (TXG) Stock Looks Expensive On Its 485% One Year Run

October 28, 2026 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Shares Cross Above Fifty Day Moving Average Following Analyst Downgrade

October 28, 2026 | americanbankingnews.com

10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference

October 27, 2026 | prnewswire.com

44,600 10x Genomics $TXG Shares Bought by Maxi Investments CY Ltd

October 27, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Stock Price Breaks Above Fifty Day Moving Average on Analyst Downgrade

October 26, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Rating Lowered to Equal Weight at Stephens

October 25, 2026 | americanbankingnews.com

1 unprofitable stock with exciting potential and 2 that underwhelm

October 23, 2026 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Given Equal Weight Rating at Stephens

October 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, FTRE, and ALMR Company Descriptions

Alamar Biosciences NASDAQ:ALMR

$29.94 +1.00 (+3.46%)

As of 01:33 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Fortrea NASDAQ:FTRE

$20.82 +0.80 (+3.97%)

As of 01:49 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Pacific Biosciences of California NASDAQ:PACB

$2.50 +0.15 (+6.17%)

As of 01:48 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

10x Genomics NASDAQ:TXG

$65.84 +4.21 (+6.83%)

As of 01:49 PM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, TXG, FTRE, and ALMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, TXG, FTRE, and ALMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, TXG, FTRE, and ALMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, FTRE, and ALMR Company Descriptions

Alamar Biosciences NASDAQ:ALMR

Fortrea NASDAQ:FTRE

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, TXG, FTRE, and ALMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, TXG, FTRE, and ALMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, TXG, FTRE, and ALMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, FTRE, and ALMR Company Descriptions

Alamar Biosciences NASDAQ:ALMR

Fortrea NASDAQ:FTRE

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools